ERGO (Entia Biosciences) LT-Debt-to-Total-Asset: 0.68 (As of Dec. 2016)


What is Entia Biosciences LT-Debt-to-Total-Asset?

Entia Biosciences ERGO LT-Debt-to-Total-Asset is 0.68 as of Dec. 2016.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Entia Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2016 was 0.68.

Entia Biosciences's long-term debt to total assets ratio increased from Dec. 2015 (0.00) to Dec. 2016 (0.68). It may suggest that Entia Biosciences is progressively becoming more dependent on debt to grow their business.

Entia Biosciences  (OTCPK:ERGO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Entia Biosciences LT-Debt-to-Total-Asset Related Terms

Entia Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences LT-Debt-to-Total-Asset Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.68

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.38 0.74 0.82 0.68

Entia Biosciences LT-Debt-to-Total-Asset Calculation

Entia Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=0.3/0.439
=0.68

Entia Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (Q: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2016 )/Total Assets (Q: Dec. 2016 )
=0.3/0.439
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.68 mean?
Entia Biosciences (ERGO) has a LT-Debt-to-Total-Asset of 0.68 as of Dec. 2016. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Entia Biosciences and its competitors.
Is Entia Biosciences' LT-Debt-to-Total-Asset too high?
Entia Biosciences' current LT-Debt-to-Total-Asset is 0.68.
How does Entia Biosciences' LT-Debt-to-Total-Asset compare to OBMP and NSPX?
Entia Biosciences' LT-Debt-to-Total-Asset of 0.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Entia Biosciences and its competitors. Entia Biosciences's current LT-Debt-to-Total-Asset is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current LT-Debt-to-Total-Asset of 0.68. The current LT-Debt-to-Total-Asset is 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current LT-Debt-to-Total-Asset is 0.68 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.